Vascular dementia (VaD) is the second leading cause of major neurocognitive disorder and is frequently associated with behavioral and psychological symptoms of dementia (BPSD), which worsen clinical outcomes and increase caregiver burden. Despite their relevance, effective pharmacological treatments for BPSD in VaD are limited. Cannabidiol (CBD), a non-psychoactive phytocannabinoid, exhibits anxiolytic, antipsychotic, and neuroprotective properties.
Objective:
To evaluate the efficacy, tolerability, and safety of CBD in reducing BPSD in older adults with VaD.
Methods:
This randomized, double-blind, placebo-controlled trial included 30 participants with VaD and clinically significant BPSD, who received either CBD (300 mg/day) or placebo for 4 weeks. Primary outcomes were changes in the Neuropsychiatric Inventory (NPI) and the Brief Psychiatric Rating Scale (BPRS) scores. Secondary outcomes included cognitive (Mini-Mental State Examination, Informant Questionnaire on Cognitive Decline in the Elderly) and functional (Katz Index, Lawton Scale) measures, along with adverse effects (Udvalg for Kliniske Undersøgelser scale). A mixed-design repeated measures analysis of variance with post hoc Sidak tests was used.
Results:
CBD significantly reduced NPI scores (interaction: F(1.58, 44.31) = 3.61, p = 0.05, partial eta squared (ηp2) = 0.11) and BPRS scores (interaction: F(2.12, 59.43) = 4.02, p < 0.05, ηp2 = 0.13) compared to placebo. No significant differences were observed in cognitive or functional outcomes. Adverse events were mild and similar between groups.
Conclusion:
CBD was well tolerated and effectively reduced BPSD in VaD without cognitive or functional impairment. These findings warrant further trials with larger samples, extended durations, and dose-optimization strategies to confirm its therapeutic potential. This study was registered at the Brazilian Clinical Trials Registry (ReBEC; ID: RBR-686kmpz, available at https://ensaiosclinicos.gov.br/rg/RBR-686kmpz).
AlexandriFPapadopoulouLTsolakiA, et al. (2024) The effect of cannabidiol 3% on neuropsychiatric symptoms in dementia – Six-month follow-up. Clinical Gerontology47(5): 800–807.
2.
American Psychiatric Association (2013) Diagnostic and Statistical Manual of Mental Disorders, 5th edn. American Psychiatric Press.
3.
BergamaschiMMQueirozRHZuardiAW, et al. (2011) Safety and side effects of cannabidiol, a Cannabis sativa constituent. Current Drug Safety6(4): 237–249.
4.
BlancaMJAlarcónRArnauJ, et al. (2017) Non-normal data: Is ANOVA still a valid option?Psicothema29(4): 552–557.
5.
BomfimAJLZuzeSMFFabrícioDM, et al. (2023) Effects of the acute and chronic administration of cannabidiol on cognition in humans and animals: A systematic review. Cannabis and Cannabinoid Research8(6): 955–973.
6.
BroersBBianchiF (2024) Cannabinoids for behavioral symptoms in dementia: An overview. Pharmacopsychiatry57(2): 71–80.
7.
BruckiSMDNitriniRCaramelliP, et al. (2003) Sugestões para o uso do mini-exame do estado mental no Brasil. Arquivos de Neuro-Psiquiatria61(3B): 777–781.
8.
CamozzatoALKochhannRSimeoniC, et al. (2008) Reliability of the Brazilian Portuguese version of the Neuropsychiatric Inventory (NPI) for patients with Alzheimer’s disease and their caregivers. International Psychogeriatrics20(2): 383–393.
9.
ChagasMHNZuardiAWTumasV, et al. (2014) Effects of cannabidiol in the treatment of patients with Parkinson’s disease: An exploratory double-blind trial. Journal of Psychopharmacology28(11): 1088–1098.
10.
ConsroePLagunaJAllenderJ, et al. (1991) Controlled clinical trial of cannabidiol in Huntington’s disease. Pharmacology Biochemistry & Behavior40(3): 701–708.
11.
CrippaJASDerenussonGNFerrariTB, et al. (2011) Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: A preliminary report. Journal of Psychopharmacology25(1): 121–30.
12.
CummingsJL (1997) The Neuropsychiatric Inventory: Assessing psychopathology in dementia patients. Neurology48(5 Suppl 6): S10–S16.
13.
de FariaSMde Morais FabrícioDTumasV, et al. (2020) Effects of acute cannabidiol administration on anxiety and tremors induced by a Simulated Public Speaking Test in patients with Parkinson’s disease. Journal of Psychopharmacology34(2): 189–196.
14.
de OliveiraAMRadanovicMde MelloPC, et al. (2015) Nonpharmacological Interventions to reduce behavioral and psychological symptoms of dementia: A systematic review. BioMed Research International2015: 218980.
15.
dos Santos SanchezMALourençoRA (2009) Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE): Adaptação transcultural para uso no Brasil. Cadernos de Saúde Pública25(7): 1455–1465.
16.
DyerSMHarrisonSLLaverK, et al. (2018) An overview of systematic reviews of pharmacological and non-pharmacological interventions for the treatment of behavioral and psychological symptoms of dementia. International Psychogeriatrics30(3): 295–309.
17.
FolsteinMFFolsteinSEMcHughPR (1975) ‘Mini-mental state’. A practical method for grading the cognitive state of patients for the clinician. Journal of Psychiatric Research12(3): 189–198.
18.
GerlachLBKalesHC (2018) Managing behavioral and psychological symptoms of dementia. Psychiatric Clinics of North America41(1): 127–139.
19.
HedlundJLViewegBW (1980) The Brief Psychiatric Rating Scale (BPRS): A comprehensive review. Journal of Psychiatric Research11: 48–65.
20.
HermushVOreLSternN, et al. (2022) Effects of rich cannabidiol oil on behavioral disturbances in patients with dementia: A placebo controlled randomized clinical trial. Frontiers in Medicine (Lausanne)9: 951889.
21.
IzzoAABorrelliFCapassoR, et al. (2009) Non-psychotropic plant cannabinoids: New therapeutic opportunities from an ancient herb. Trends in Pharmacological Sciences30(10): 515–527.
22.
KalesHCGitlinLNLyketsosCG (2015) Assessment and management of behavioral and psychological symptoms of dementia. British Medical Journal350: h369.
23.
KatzSFordABMoskowitzRW, et al. (1963) Studies of illness in the aged. The index of ADL: A standardized measure of biological and psychosocial function. Journal of the American Medical Association185: 914–919.
24.
KuharicDBMarkovicDBrkovicT, et al. (2021) Cannabinoids for the treatment of dementia. Cochrane Database of Systematic Reviews9(9): CD012820.
25.
LawtonMPBrodyEM (1969) Assessment of older people: Self-maintaining and instrumental activities of daily living. Gerontologist9(3): 179–186.
26.
LingjaerdeOAhlforsUGBechP, et al. (1987) The UKU side effect rating scale: A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatrica Scandinavica334: 1–100.
27.
LinoVTSPereiraSRMCamachoLAB, et al. (2008) Adaptação transcultural da Escala de Independência em Atividades da Vida Diária (Escala de Katz). Cadernos de Saúde Pública24(1): 103–112.
28.
NeumannRDFarisPKlassenR (2015) Examining trends in the administration of ‘as needed’ medications to inpatients with behavioral and psychological symptoms of dementia. American Journal of Alzheimer’s Disease and other Dementias30(3): 247–256.
PatelSHillMNCheerJF, et al. (2017) The endocannabinoid system as a target for novel anxiolytic drugs. Neuroscience and BioBehavioral Reviews76: 56–66.
31.
PengJFanMAnC, et al. (2022) A narrative review of molecular mechanism and therapeutic effect of cannabidiol (CBD). Basic & Clinical Pharmacology & Toxicology130(4): 439–456.
32.
PessoaRMPMaximiano-BarretoMALambertL, et al. (2023) The frequency of psychotic symptoms in types of dementia: A systematic review. Dementia &Neuropsychologia17: e20220044.
33.
PisaniSMcGoohanKVelayudhanL, et al. (2021) Safety and tolerability of natural and synthetic cannabinoids in older adults: A systematic review and meta-analysis of open-label trials and observational studies. Drugs & Aging38(10): 887–910.
34.
RyanDDrysdaleAJLafourcadeC, et al. (2009) Cannabidiol targets mitochondria to regulate intracellular Ca2+ levels. Journal of Neuroscience29(7): 2053–2063.
35.
ShelefABarakYBergerU, et al. (2016) Safety and efficacy of medical cannabis oil for behavioral and psychological symptoms of dementia: An-open label, add-on, pilot study. Journal of Alzheimer’s Disease51(1): 15–19.
36.
SkrobotOAO’BrienJBlackS, et al. (2017) The vascular impairment of cognition classification consensus study. Alzheimer’s & Dementia13(6): 624–633.
37.
TibleOPRieseFSavaskanE, et al. (2017) Best practice in the management of behavioural and psychological symptoms of dementia. Ther Adv Neurol Disord10(8): 297–309.
38.
VelayudhanLMcGoohanKBhattacharyyaS (2021) Safety and tolerability of natural and synthetic cannabinoids in adults aged over 50 years: A systematic review and meta-analysis. PLoS Medicine18(3): e1003524.
39.
WaltherSHalpernM (2010) Cannabinoids and dementia: A review of clinical and preclinical data. Pharmaceuticals (Basel)3(8): 2689–2708.
40.
WassertheilSCohenJ (1970) Statistical power analysis for the behavioral sciences. Biometrics26(3): 588.
41.
WolfSABick-SanderAFabelK, et al. (2010) Cannabinoid receptor CB1 mediates baseline and activity-induced survival of new neurons in adult hippocampal neurogenesis. Cell Communication and Signaling8: 12.
42.
YangSDuYZhaoX, et al. (2022) Cannabidiol enhances microglial beta-amyloid peptide phagocytosis and clearance via vanilloid family type 2 channel activation. International Journal of Molecular Sciences23(10): 5367.
43.
ZlebnikNECheerJF (2016) Beyond the CB1 receptor: Is cannabidiol the answer for disorders of motivation?Annual Review of Neuroscience39: 1–17.
44.
ZuardiAWLoureiroSRRodriguesCRC, et al. (1994) Estudo da estrutura fatorial, fidedignidade e validade da tradução e adaptação para o português da Escala de Avaliação Psiquiátrica Breve (BPRS) modificada. Revista ABP-APAL16: 63–68.
45.
ZuardiAWCrippaJASHallakJEC, et al. (2009) Cannabidiol for the treatment of psychosis in Parkinson’s disease. Journal of Psychopharmacology23(8): 979–983.
46.
ZuardiAWCrippaJAHallakJE, et al. (2012) A critical review of the antipsychotic effects of cannabidiol: 30 Years of a translational investigation. Current Pharmaceutical Design18(32): 5131–5140.
